$ News

How Investors Are Reacting To Shionogi (TSE:4507) Clinical Trial Results

IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja®/Fetcroja® (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory Infections

Shionogi and F2G’s invasive aspergillosis drug shows long-term benefit

Shionogi & Co. (SGIOY) Upgraded to Buy: Here's What You Should Know

Can Shionogi (TSE:4507) Support Its Price With Earnings After IntraBio?

Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout

Shionogi acquires rare disease startup IntraBio for $2 billion

Shionogi pays $2B to acquire a rare disease startup

Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc.

Shionogi & Co Ltd's Dividend Analysis

Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026

Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats

Shionogi & Co., Ltd. 2027 Q1 - Results - Earnings Call Presentation

Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth

Shionogi & Co., Ltd. (SGIOY) Shareholder/Analyst Call - Slideshow

Shionogi (TSE:4507) Valuation Check As XOCOVA Wins First US FDA Approval For COVID 19 Post Exposure Prophylaxis

Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure

Shionogi & Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation

New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure

Shionogi’s Fetroja Contract And Data Shift U.S. Growth And Valuation Outlook